Thrombosthenia
Thrombasthenia is a hereditary bleeding disease characterized by low or absent response of blood cells to a variety of physiological aggregation inducers. It is caused by qualitative or quantitative abnormalities of platelet membrane glycoprotein IIb (GPⅡb) and/or IIIa (GPⅢa).
-
Site of disease:
Blood vessels -
Infectious :
Not contagious -
Frequent population:
child -
Related symptoms:
Skin and mucous membrane bleeding Gum bleeding Internal bleeding Intracranial bleeding Gum bleeding -
Concurrent disease:
Related Drugs
Norethindrone dripping pills
Indication: Used for short-term contraception when women visit relatives.
Manufacturer:
Tianjin Lisheng Pharmaceutical Co., Ltd.
Folic acid tablets
Indication: 1. Used for folic acid deficiency caused by various reasons and megaloblastic anemia caused by folic acid deficiency; 2. Preventive administration for pregnant and lactating women; 3. Folic acid deficiency caused by chronic hemolytic anemia.
Manufacturer:
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Related Ingredients